Manila Times Business
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
Study published in Stem Cell Reportsdemonstrates that AstroRx® - a therapy derived from NewcelX’s platform -addresses key barriers toremyelination with potential to treat chronic demyelinating diseases including MS Showcases scalability and broad therapeuticpotential of the Company’s stem cell therapy platformas it advancesa potential cure for type 1 diabetes ZURICH, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company develop
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Twenty-six years later: Finally seeing the first sunrise at Pusan Point
Just now
BSB Junrose strengthens portfolio for hybrid, EV, and conventional vehicles
Just now
FAW trucks launches 'Wheels of Hope' outreach for Rizal school
Just now
Toyota unveils GRMN Corolla with no rear seats and Nürburgring-focused upgrades
Just now